Company profile for Titan Pharmaceuticals Inc

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Titan is a specialty pharmaceuticals company that develops therapeutics for select chronic diseases utilizing its innovative, long-term, continuous drug delivery platform, ProNeura. The company's lead product is Probuphine, a six-month buprenorphine implant for the maintenance treatment of opioid addiction. The U.S. Food and Drug Administration approved Probuphine on May 26, 2016. Probuphine is the first marketed product to pr...
Titan is a specialty pharmaceuticals company that develops therapeutics for select chronic diseases utilizing its innovative, long-term, continuous drug delivery platform, ProNeura. The company's lead product is Probuphine, a six-month buprenorphine implant for the maintenance treatment of opioid addiction. The U.S. Food and Drug Administration approved Probuphine on May 26, 2016. Probuphine is the first marketed product to provide maintenance treatment of opioid addiction continuously for six months following a single administration procedure.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
400 Oyster Point Boulevard, Suite 505 South San Francisco, CA 94080-1958
Telephone
Telephone
650-244-4990
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2025/06/27/3106813/0/en/Titan-Pharmaceuticals-Announces-600-000-Private-Placement-of-Convertible-Preferred-Stock.html

GLOBENEWSWIRE
27 Jun 2025

https://www.globenewswire.com/news-release/2025/06/03/3092778/0/en/Titan-Pharmaceuticals-Announces-Filing-of-Registration-Statement-for-Proposed-Business-Combination-with-TalenTec-Sdn-Bhd.html

GLOBENEWSWIRE
03 Jun 2025

https://www.globenewswire.com/news-release/2025/04/11/3060338/0/en/Titan-Pharmaceuticals-Announces-1-Million-Private-Placement-of-Convertible-Preferred-Stock.html

GLOBENEWSWIRE
11 Apr 2025

https://www.globenewswire.com/news-release/2024/11/27/2988437/0/en/Titan-Pharmaceuticals-Inc-Announces-Receipt-of-Notice-from-Nasdaq.html

GLOBENEWSWIRE
27 Nov 2024

https://www.globenewswire.com/news-release/2024/08/19/2932437/0/en/Titan-Pharmaceuticals-Enters-Into-Merger-Agreement-With-KE-Sdn-Bhd.html

GLOBENEWSWIRE
19 Aug 2024

https://www.globenewswire.com//news-release/2024/01/25/2817418/0/en/Titan-Pharmaceuticals-Fully-Compliant-With-NASDAQ-Listing-Criteria.html

GLOBENEWSWIRE
25 Jan 2024

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty